Published in Blood on November 10, 2009
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov (2011) 2.45
Cell-surface proteomics identifies lineage-specific markers of embryo-derived stem cells. Dev Cell (2012) 1.37
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood (2012) 1.03
Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology (2012) 0.99
BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer. Virology (2013) 0.87
Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation. Protein Eng Des Sel (2014) 0.87
Direct detection of biotinylated proteins by mass spectrometry. J Proteome Res (2014) 0.87
Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells. PLoS One (2013) 0.86
Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis. Breast Cancer Res (2014) 0.84
Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells. J Virol (2011) 0.82
Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells. PLoS One (2015) 0.79
The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells. Blood Cancer J (2014) 0.78
A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2. Sci Rep (2015) 0.77
New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010. J Hematop (2010) 0.75
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood (2007) 5.18
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood (2013) 3.03
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med (2009) 2.80
Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nat Nanotechnol (2011) 2.79
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol (2007) 2.35
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol (2005) 1.96
Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood (2012) 1.82
Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica (2008) 1.80
CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood (2012) 1.79
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol (2010) 1.79
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med (2008) 1.74
Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology (2013) 1.71
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood (2013) 1.71
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation. Nat Chem Biol (2010) 1.66
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol (2008) 1.60
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer (2002) 1.53
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood (2011) 1.51
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One (2009) 1.48
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol (2012) 1.46
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.45
Fibronectin as target for tumor therapy. Int J Cancer (2006) 1.44
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood (2008) 1.42
Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics (2005) 1.42
Encoded self-assembling chemical libraries. Nat Biotechnol (2004) 1.40
Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood (2011) 1.39
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer (2008) 1.36
The RNA subunit of telomerase is encoded by Marek's disease virus. J Virol (2003) 1.32
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res (2003) 1.31
Selective targeted delivery of TNFalpha to tumor blood vessels. Blood (2003) 1.29
Carbon nanotubes elicit DNA damage and inflammatory response relative to their size and shape. Inflammation (2010) 1.27
Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res (2011) 1.27
Differentiation of in vitro-modified human peripheral blood monocytes into hepatocyte-like and pancreatic islet-like cells. Gastroenterology (2005) 1.26
The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res (2007) 1.26
Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica (2007) 1.25
A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood (2006) 1.25
Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood (2003) 1.25
Systemic distribution, nuclear entry and cytotoxicity of amorphous nanosilica following topical application. Biomaterials (2011) 1.25
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 1.23
Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol (2010) 1.21
Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood (2003) 1.21
PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene (2003) 1.21
Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica (2009) 1.20
Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today (2012) 1.20
High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries. Proc Natl Acad Sci U S A (2008) 1.18
Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release (2012) 1.18
Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol (2011) 1.16
Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. Haematologica (2008) 1.15
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res (2007) 1.14
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood (2012) 1.14
Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study. Proteomics (2004) 1.14
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol (2002) 1.12
In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res (2010) 1.10
Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library. Angew Chem Int Ed Engl (2007) 1.10
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol (2014) 1.10
Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta (2007) 1.08
Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics (2004) 1.08
Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop (2009) 1.07
Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol (2008) 1.07
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma (2012) 1.07
Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer (2009) 1.06
Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem (2007) 1.06
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer (2005) 1.06
Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica (2013) 1.05
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol (2008) 1.05
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics (2006) 1.03
Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol (2008) 1.03
Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood (2013) 1.03
Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol (2007) 1.03
Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes. Part Fibre Toxicol (2011) 1.03
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer (2008) 1.03
Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice. Part Fibre Toxicol (2013) 1.03
Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. Nanotechnology (2012) 1.02
Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation. Br J Haematol (2009) 1.02
Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol (2013) 1.01
Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. J Pathol (2005) 1.01
Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res (2003) 1.01
DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries. Acc Chem Res (2014) 1.01
Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res (2008) 1.01
Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol (2011) 1.00
Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol (2010) 1.00